TARIS Biomedical® Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments

  TARIS Biomedical® Enters Research Collaboration with AstraZeneca for
  Improved Bladder Cancer Treatments

Business Wire

LEXINGTON, Mass. -- October 16, 2013

TARIS Biomedical^®, a specialty pharmaceutical company developing innovative,
targeted therapies to treat bladder diseases with high unmet medical need,
announced today that it has entered into a research collaboration with
AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms
of the agreement, the companies will work together to evaluate multiple novel
cancer therapeutics by employing the TARIS^® proprietary bladder delivery
platform in combination with targeted cancer therapeutics from AstraZeneca.
The TARIS^® delivery platform is a soft, flexible system deployed into and
retrieved from the bladder using standard urological office procedures. It is
designed to provide continuous local delivery to the bladder for days to
weeks, depending on the therapeutic application. Furthermore, AstraZeneca has
an exclusive option to take a license to the products resulting from the
collaboration.

"We are excited to collaborate with AstraZeneca, a leading global
biopharmaceutical company committed to developing innovative cancer
medicines,” said Purnanand Sarma, PhD, President and CEO, TARIS Biomedical^®.
“Through this collaboration, TARIS^® will have the opportunity to evaluate its
proprietary bladder delivery platform in an oncology setting, potentially
providing multiple novel product candidates to treat bladder cancer. Treatment
options in bladder cancer are poor, and we believe our technology has the
potential to revolutionize the treatment in this area. Collaboration with
AstraZeneca is a validation of the potential of our technology, and leverages
the TARIS^® know-how in bladder delivery and bladder cancer, one of the
several therapeutic areas of focus for the company.”

“AstraZeneca is committed to the development of innovative medicines for the
treatment of cancer that make a meaningful difference to the lives of cancer
patients,” said Susan Galbraith, Head of the Oncology Innovative Medicines
Unit at AstraZeneca. “We are excited to have the opportunity to collaborate
with TARIS^® because their novel technology has the potential to enable the
delivery of the right drugs to the tumour tissue in the right concentration
and over a prolonged period. This could combine the ability to target both the
right tissue - the tumour, with the right genetically targeted therapy and
therefore represent a step change in the treatment of this disease.”

About Bladder Disease

Bladder diseases, which are difficult to treat with systemic therapies, affect
60 million people in the U.S. alone. These diseases include interstitial
cystitis (IC)/bladder pain syndrome (BPS), bladder cancer, overactive bladder,
urinary tract infections and chronic pelvic pain syndromes.

About Bladder Cancer

Bladder cancer is difficult to treat, and there is a high unmet medical need.
In many cases patients undergo repeated surgeries including removal of the
bladder. The knowledge of the different genetic abnormalities which drive
bladder cancer growth in different patients is enabling the development of
better targeted therapies.

With more than 500,000 people affected in the US and more than 70,000 new
cases annually, bladder cancer represents the fourth most common cancer in men
and the fifth most common cancer overall. The disease represents a ~$3.98B
(direct costs only) annual burden on the healthcare system in the United
States. Worldwide prevalence is reported to be 2.7 million with an incidence
of 350,000. Better outcomes and reduced disease recurrence are serious unmet
needs for bladder cancer patients.

About TARIS Biomedical^®

TARIS Biomedical^® is a clinical stage specialty pharmaceutical company
focused on developing a pipeline of innovative treatments for bladder
diseases. Current therapies for these conditions are characterized by limited
efficacy and/or systemic side effects. The TARIS Biomedical^® delivery
platform is designed to improve treatment by providing controlled, sustained
delivery of drug directly to target tissues. TARIS^® is currently pursuing
opportunities in bladder cancer, overactive bladder and Interstitial cystitis.
The most advanced TARIS^®  product candidate, LiRIS^®, is currently in Phase 2
clinical development for the treatment of interstitial cystitis.

The TARIS^® technology was developed by internationally renowned scientists
from the Massachusetts Institute of Technology, Robert Langer and Michael
Cima. Based in Lexington, MA, TARIS Biomedical^® is backed by leading venture
capital firms Flagship Ventures, Flybridge Capital Partners, Polaris Partners
and Third Rock Ventures. For more information, visit www.tarisbiomedical.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit:www.astrazeneca.com.

Contact:

TARIS Biomedical^®
Christopher Searcy, 781‐676‐7750
Chief Business Officer,
or
Media Contact:
Gina Nugent, 617-460-3579
nugentcomm@aol.com
 
Press spacebar to pause and continue. Press esc to stop.